Merck Fosamax patent upheld
Executive Summary
Merck's Fosamax (alendronate) will not face generic competition until at least August 2007, following a decision by Wilmington, Del., federal court to uphold a method of use patent for the osteoporosis drug Nov. 4. Teva intends to appeal the decision...
You may also be interested in...
Merck Fosamax once-weekly patent upheld
Merck Fosamax once-weekly dose will not face generic competition until 2019, under a ruling by the Wilmington, Del. federal court to uphold a method of use patent (no. 5,994,329) for the 35 mg and 70 mg strengths of the osteoporosis agent. Teva plans to appeal the decision; the company is also awaiting a ruling on its appeal of the same court's decision to uphold Merck's method of use patent covering the Fosamax (alendronate) once-daily products (1"The Pink Sheet" Nov. 11, 2002, In Brief)...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.